Ovarian Cancers

Written with the busy practice in mind, this book delivers clinically focused, evidence-based gynecology guidance in a quick-reference format. It explores etiology, screening, tests, diagnosis, and treatment for a full range of gynecologic health issues. The coverage includes the full range of gynecologic malignancies, reproductive endocrinology and infertility, infectious diseases, urogynecologic problems, gynecologic concerns in children and adolescents, and surgical interventions including minimally invasive surgical procedures. Information is easy to find and absorb owing to the extensive use of full-color diagrams, algorithms, and illustrations. The new edition has been expanded to include aspects of gynecology important in international and resource-poor settings.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.

Now in its third edition! Ovarian Carcinoma is an invaluable source of information because it gives a complete overview of all aspects: histologic classification, FIGO staging, tumor markers, symptoms, diagnosis, operative treatment, chemotherapy, radiation therapy, complications such as pregnancy and AIDS, biological response modifiers and the status of clinical trials. The new chapter on biologic response modification is especially noteworthy since it reports on new developments now being tested in clinical trials. All the other chapters have been expanded and updated, too. At the same time, the author has kept his clear, readable style that makes the book easy to understand. The contents are based on actual clinical experience and thus extremely practical.

This unique guide for ovarian cancer gives women crucial medical information to improve the chance for lengthy remission and cure, as well as emotional support for the journey. Although many ovarian cancers are discovered after they have spread, having information about surgery and best practices can be life-saving. For example, choosing a surgeon from the new specialty of gynecologic oncology for staging and de-bulking surgeries strongly impacts survival. Women need to at least consider newer chemotherapy and biological treatments in research trials. Women also want to hear the stories of others who live with the ambiguity of remission. Ovarian Cancer includes: Ten things to know at the time of diagnosis, for optimal outcome How choosing a gynecologic oncology surgeon impacts survival When and how you can consider newer treatments, now in clinical trials Stories of dozens of women living with ovarian cancer, some for many years ""Questions for Your Doctor"" for all decision points A focus on epithelial cancers, the most common and difficult to treat, with additional information on germ cell, sex cord-stromal cell, and low malignant potential ovarian cancers Noted cancer writer Kristine Conner and patient advocate Lauren Langford provide ovarian cancer patients with a supportive and much-needed resource.

In den letzten Jahren kam es zu einem noch nie dagewesenen Anstieg unseres Wissens über das Management des Ovarialkarzinoms; von Diagnose und Genetik bis hin zur Operation und neuen zielgerichteten Behandlungsmethoden. Das bedeutet, dass sich für den gut informierten Mediziner in Bezug auf die Diagnose und Behandlung von Frauen mit Ovarialkarzinom oder dem Verdacht auf Ovarialkarzinom mehrere Möglichkeiten zur sinnvollen Intervention bieten. Dieses Buch bietet eine umfassende Übersicht über alle Versorgungsebenen, fasst die aktuellen Fortschritte zusammen und stellt sie in klinischen Kontext. Es beantwortet wichtige Fragen, wie wann operiert werden und wann eine Behandlung mit konventionellen bzw. mit neuartigen Modalitäten durchgeführt werden sollte. Inhalt: • Epidemiologie und Prophylaxe • Pathophysiologie und Klassifizierung • Gentests • Diagnose, Staging und Grading • Operation • Chemotherapie • Rezidivierendes Ovarialkarzinom • Zielgerichtete Therapien • Nicht-epitheliale Ovarialkarzinome • Nachsorge und palliative Operation • Hilfreiche Adressen

Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers.

This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level.